Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Obesity: early-phase trial registry
306 of 1,057 indexed Obesity trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3 of 28,707 conditions by registered trial count.
1,057 US clinical trials · 306 currently recruiting · #3 of 28,707 conditions by registered trial count
Obesity: 1,057 US clinical trials tracked, 306 recruiting.
Obesity is the subject of 1,057 registered US clinical trials on ClinicalTrials.gov, 306 of them currently open to new participants. 107 are in Phase 3-4 (later-stage) and 196 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 48 of these trials.
Enrollment posture brief
Registry condition obesity
OPEN 306 | RECR 29% | LATE 107 | EARLY 196 | RANK #3 | SPON 48
Volume-matched condition peers
Nearest open-share peer: Metastatic Pancreatic Adenocarcinoma (29% recruiting · 38 trials)
Obesity lists 306 open slots (29% of 1,057 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Obesity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Obesity is recruiting below its size-band peers.
306 of 1,057 indexed trials (28.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Obesity trials is spread across many organizations.
Eli Lilly and Company accounts for 48 of 1,057 trials (4.5%). 314 distinct sponsors appear on at least one study for this condition label.
-
Typical Obesity enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,054 trials that report a genuine target (sentinel values excluded). 555 of those (52.7%) plan for fewer than 100 participants.
-
Obesity research is mostly interventional.
894 interventional and 163 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,057 total, page 10 of 22
Angiotensin-(1-7) and Energy Expenditure in Human Obesity
Amy Arnold
NCT03777215
Anti-obesity Pharmacotherapy and Inflammation
Louisiana State University Health Sciences Center in New Orleans
NCT05756764
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
Mayo Clinic
NCT05264727
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
Mayo Clinic
NCT06801015
Saxenda: Underlying Mechanisms and Clinical Outcomes
Beth Israel Deaconess Medical Center
NCT02944500
Epigenetic Regulation of Human Adipose Tissue Distribution
AdventHealth Translational Research Institute
NCT02728635
Study of Changes in Skeletal Muscle After Caloric Restriction
Vanderbilt University
NCT00993460
Bariatric Surgery Versus Diet Alone in the Bile Acid Pathway and Weight Loss
Mayo Clinic
NCT03238794
WeighT LOSS Surgery and Comprehensive Cardiometabolic Responses to to EXercise
Massachusetts General Hospital
NCT06576050
The Effects of Glucagon on Hepatic Metabolism
Adrian Vella
NCT05500586
Evaluation of Bariatric Endoscopic Antral Myotomy (BEAM) as a Treatment for Obesity
Brigham and Women's Hospital
NCT05713071
Enhancing Mental and Physical Health of Women Veterans
VA Office of Research and Development
NCT05050266
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
University of Kansas Medical Center
NCT06485089
To Determine Tolerability to Glucagon Infusion in Obese Subjects
AdventHealth Translational Research Institute
NCT02817659
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
Brigham and Women's Hospital
NCT04820036
Determine How Consumption of Dairy Fat as Cheese Influences Inflammation-Phase 2
University of California, Davis
NCT01803633
Evaluation of Patient Coach Support for Older Adults With Obesity
University of Michigan
NCT06624163
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
Rhythm Pharmaceuticals
NCT06772597
Body Weight, Sleep, and Heart Health
Oregon Health and Science University
NCT03388788
Endoscopic Gastric Mucosal Ablation as a Primary Obesity Therapy
Erbe Elektromedizin
NCT05486338
ABLATE WEIGHT (Ablation Plus ESG for Weight Loss)
True You Weight Loss
NCT05578703
CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users
University of California, Davis
NCT06467604
Probiotics and Insulin Resistance in Obese Asthmatics
University of Alabama at Birmingham
NCT05949255
Long-Term Exercise Maintenance Via Internet Support
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00260117
Testing Product Messages in Colombia
University of North Carolina, Chapel Hill
NCT05783726
Cooking for Health Optimization With Patients
Tulane University
NCT03443635
Comparison of Outreach Methods to Encourage Enrollment in Diabetes Prevention and Weight Management Programs
Kaiser Permanente
NCT03200535
Effects of Infant Egg Consumption on Child Health and Cognition Development
State University of New York at Buffalo
NCT04345185
Extracellular RNAs in Relation to Cardiometabolic Risk
National Heart, Lung, and Blood Institute (NHLBI)
NCT03225196
Gene x Behavior Interaction in the Look AHEAD Study
The Miriam Hospital
NCT01270763
Mass in Motion Kids in the Clinical Setting
Massachusetts General Hospital
NCT02110615
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Novo Nordisk A/S
NCT01272219
SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial
Novo Nordisk A/S
NCT04972721
A School-based Gardening Obesity Intervention for Low-income Minority Children
University of Texas at Austin
NCT02668744
Body Worlds 3 Nutrition Display
Oregon Health and Science University
NCT00669500
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
VIVUS
NCT00553787
Diabetes Prevention Strategies in Women With Gestational Diabetes Mellitus (GDM)
Kaiser Permanente
NCT01344278
Effects of Sugary Drinks Counter-marketing Messages
Stanford University
NCT05953194
Metabolism, Breastmilk, and Microbiome
University of Minnesota
NCT03522597
Weight Stigma by Association in Parent-Child Dyads
University of California, Los Angeles
NCT04829162
Environmental Intervention for Weight Gain Prevention
University of Minnesota
NCT00708461
Tribal Health and Resilience in Vulnerable Environments
University of Oklahoma
NCT03311217
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company
NCT05872620
Does the Presence of Preoperative Proteinuria Predict Postoperative Acute Kidney Injury in Obese Patients Undergoing Elective Laparoscopic Surgery?
NYU Langone Health
NCT02798042
The Active by Choice Today (ACT) Trial to Increase Physical Activity
University of South Carolina
NCT01028144
"Working for You" Workplace Obesity Intervention
Washington University School of Medicine
NCT02934113
Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults
VIVUS
NCT00554216
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
Novo Nordisk A/S
NCT03552757
Study of a Holistic Health Program for United Methodist Clergy
Duke Clergy Health Initiative
NCT01564719
A Natural Experiment Evaluating the Effect of a Minimum Wage Increase on Obesity and Diet-related Outcomes
University of Connecticut
NCT03962712
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 95 |
| Phase 2 | 101 |
| Phase 3 | 69 |
| Phase 4 | 38 |
Top Sponsors
Named interventions
Most-linked intervention names on Obesity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Obesity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Obesity page
1,057 registered trials, 306 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 306 Obesity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Obesity trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Obesity condition card totals 1,057 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.